Andrew James King, Chief Scientific Officer at CHINOOK THERAPEUTICS, INC. (KDNY), sold 5,000 shares at $23.34 ($117K) on 2023-04-03, disclosed to the SEC on 2023-04-05.
Scheduled sale ($117k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KDNY | SELL | 2023-02-02 | $160K | — | Filing → |
| KDNY | SELL | 2023-01-04 | $258K | — | Filing → |
| KDNY | SELL | 2022-10-11 | $140K | — | Filing → |